Your browser doesn't support javascript.
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
Lombardi, Andrea; Bozzi, Giorgio; Ungaro, Riccardo; Villa, Simone; Castelli, Valeria; Mangioni, Davide; Muscatello, Antonio; Gori, Andrea; Bandera, Alessandra.
  • Lombardi A; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Bozzi G; Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy.
  • Ungaro R; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Villa S; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Castelli V; Center for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan, Italy.
  • Mangioni D; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Muscatello A; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Gori A; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Bandera A; Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Front Immunol ; 12: 657711, 2021.
Article in English | MEDLINE | ID: covidwho-1156127
ABSTRACT

Background:

BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination.

Methods:

We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided.

Results:

BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported.

Discussion:

BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Immunization / Immunogenicity, Vaccine / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.657711

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Immunization / Immunogenicity, Vaccine / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.657711